A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate t
Read time: 2 mins
Last updated:1st Apr 2013
Primary Sponsor: Novartis Pharmaceuticals
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
|Date last updated at source||2016-01-19|
|Study start date||2013-04-01|
|Estimated primary completion date||2013-04-01|